相关实验视频
Updated: Jul 20, 2025

06:21
Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
10.5K
莱涅佐利德诱导的低血糖和贫血:一个病例报告
Xiao-Hua Lan1,2, Yue Hu1,3, Yan-Jie Cao1
1Air Force Medical Center, PLA Beijing China.
Clinical case reports
|August 2, 2023
概括
利尼佐利德 (LZD) 可能会引起罕见但严重的副作用,如低血糖和贫血,特别是在老年患者中. 在长期的LZD治疗期间,监测血糖和例行测试至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
- 传染性疾病 传染性疾病
背景情况:
- 线化物 (LZD) 是对多药耐药细菌的重要抗生素.
- 对LZD的不良反应虽然很少见,但可能是严重的,包括低血糖和贫血.
- 长期使用LZD,特别是在弱势群体中,需要仔细监测.
研究的目的:
- 报告linezolid引起的第一个复发性低血糖和贫血病例.
- 突出LZD在老年患者中可能产生严重不良影响的潜力.
- 强调警监测LZD相关毒性的重要性.
主要方法:
- 一个93岁的患者的案例研究,用LZD治疗结核病.
- 详细监测血糖,血细胞计数和肝/功能.
- 使用Naranjo的不良药物反应评估尺度来评估因果关系.
主要成果:
- 患者在5天和2周的LZD治疗后分别出现了复发性低血糖和贫血.
- 纳兰乔的尺度表明LZD和不良事件之间可能存在联系 (得分为8).
- 症状在停用LZD后一个月内消失.
结论:
- 利尼佐利德可以诱导严重的低血糖和贫血,即使在罕见的情况下.
- 老年患者和肝脏或功能受损患者的风险更高.
- 在LZD治疗期间,定期监测血液参数和葡萄糖水平至关重要.
相关概念视频
Hypoglycemia and Glucagon
301
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
301
Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Insulin: Dosing Regimen and Adverse Effects
209
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
209
Oral Hypoglycemic Agents: Glinides
186
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
186
Chronic Kidney Disease II: Clinical Manifestations
30
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
30
SBAR II: Application of SBAR
4.5K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.5K

